Tirzepatide in the United States
Tirzepatide is back under the regulated umbrella in the US after the Feb-Mar 2026 reclass. Prices stayed stubbornly high. The compounded alternative is cheaper but the trust profile depends entirely on the 503A/503B source.
Tirzepatide is FDA-approved for Type 2 Diabetes (Mounjaro) and obesity (Zepbound). Prescription-only. 503A compounding is permitted under current rules (April 2026) but remains under FDA scrutiny.
What it actually costs.
Midpoint ranges, Eli Lilly brand unless noted. Updated April 2026.
Per month, Eli Lilly list. Insurance dependent — some plans cover, most do not.
Same molecule, different distribution. Quality depends on the pharmacy.
Henry, Mochi, Ro, LifeMD. Includes consult + shipping.
How to get it — on the right side of the line.
Branded through insurance or cash
If your plan covers Zepbound for weight management, copay is the path. Otherwise cash at a regular pharmacy runs near list.
Compounded via a telehealth service
Ro, Henry Meds, Mochi, LifeMD, Hims. The Panya rubric scores each on cold-chain, COA, response time. Expect $297 to $400 monthly all-in.
What channels actually work here.
Standard retail pharmacy.
503A pharmacies, stable supply, state variance.
Grey-market — not recommended by Panya.
Major growth channel. Low-friction onboarding.
US telehealth services typically require a 5-to-10-minute intake form + short video call. Insurance is secondary to the compounded cash price for most users.
Match me to a vendor in the US.
Two minutes, five questions. Your match email has the vendor name, price, and the honest tradeoff.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.